Phase 2 Parkinson's Disease Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been confirmed through a tissue or cell sample test to have Stage IV non-small cell lung cancer (NSCLC), either the squamous or non-squamous type
• People with non-squamous NSCLC for whom a doctor-approved targeted therapy is not considered suitable
• People who are able to provide a tumor tissue sample — either one stored from within the last 5 years (or since completing their last treatment), or a newly collected biopsy taken from an area not previously treated with radiation, within 90 days before starting the trial treatment
• People who have not yet received any systemic (whole-body) treatment for their advanced/metastatic NSCLC
• People who are able to complete all required pre-trial check-ups within 35 days (Part A) or 28 days (Part B) of beginning the screening process

Who may not be able to join:

• People who have been diagnosed with small cell lung cancer
• People who have an immune system deficiency, or who have been taking steroid medications above a certain daily dose, or any other immune-suppressing medication in the 7 days before the first trial treatment
• People who have another cancer (in addition to NSCLC) that is currently growing or has required active treatment within the past 2 years
• People who have active cancer spread to the brain or spinal fluid lining (confirm with trial site)
• People who have an autoimmune disease that has needed systemic (whole-body) treatment within the past 2 years
• People who have a history of lung inflammation (not caused by infection) that required steroid treatment, or who currently have lung inflammation
• People who have an active infection that requires systemic (whole-body) treatment
• People with serious heart conditions, including unstable chest pain, a heart attack within the past 6 months, or severe heart failure
• People with a known history of HIV infection — though people with well-controlled HIV managed with anti-retroviral therapy are not automatically excluded
• People with known Hepatitis B surface antigen in their blood, unless they have been on Hepatitis B antiviral treatment for at least 4 weeks and their viral load is undetectable before the trial begins; people with active Hepatitis C infection are not eligible
• People who have had major surgery within 3 weeks before the first trial treatment
• People who are expected to need another form of cancer treatment during the trial
• People who have a bowel condition (such as Crohn's disease or ulcerative colitis), significantly impaired liver function, or another condition that a doctor believes could interfere with how oral medications are absorbed or processed
• People receiving chemotherapy who have active diverticulitis, an abscess in the abdomen, a bowel blockage, or cancer spread throughout the abdominal cavity
• People who already have moderate or worse nerve damage (neuropathy)
• People who have previously received systemic chemotherapy, targeted therapy, or biological cancer treatment for their metastatic disease
• People who are unwilling or unable to take folic acid or vitamin B12 supplements, if they are assigned to receive a chemotherapy drug called pemetrexed
• People with a known allergy or sensitivity to carboplatin, paclitaxel, pemetrexed, or any of their ingredients
• People who have received radiation to the lung above a certain dose level within 6 months before the first trial treatment
• People who have received a live vaccine within 30 days before the first trial treatment — approved COVID-19 mRNA, adenoviral, or inactivated vaccines are permitted, but investigational (unapproved) vaccines are not
• People who have previously received immunotherapy and had to stop it due to a severe or worse immune-related side effect
• People who have had chemotherapy or biological cancer therapy within 4 weeks before the first trial treatment, or whose side effects from earlier cancer treatment have not sufficiently resolved
• People who are currently taking part in, or have taken part in, another clinical trial involving an experimental treatment or device within the past 4 weeks
• People who have previously had a severe allergic reaction to a monoclonal antibody treatment (including pembrolizumab) or any of their ingredients
• People who have received a transplant of donor tissue or a solid organ

Important: Always verify eligibility with the trial site directly before applying.